

Resource Summary Report

Generated by RRID on Aug 4, 2026

Statistical Analysis System

RRID:SCR_008567

Type: Tool

Proper Citation

Statistical Analysis System (RRID:SCR_008567)

Resource Information

URL: <http://www.sas.com>

Proper Citation: Statistical Analysis System (RRID:SCR_008567)

Description: Software platform to explore, analyze and visualize data. SAS 9.4 is part of SAS Platform. Standardized data governance and management from statistical software company SAS.

Abbreviations: SAS

Synonyms: Statistical Analysis System, SAS Intelligence Platform, SAS 9.3, SAS 9.4

Resource Type: data management software, software resource, software application, data analytics software

Keywords: Explore, analyze, visualize, data, standardized, management, statistics

Availability: Restircted

Resource Name: Statistical Analysis System

Resource ID: SCR_008567

Alternate IDs: nif-0000-31484

Alternate URLs: https://www.sas.com/en_us/software/platform.html,
https://www.sas.com/en_us/software/sas9.html

Record Creation Time: 20220129T080248+0000

Record Last Update: 20260804T043351+0000

Ratings and Alerts

No rating or validation information has been found for Statistical Analysis System.

No alerts have been found for Statistical Analysis System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 7165 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Rugo HS, et al. (2026) Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 179.

Huang MH, et al. (2026) Risk of Stroke in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Cohort Study of 183,504 Subjects. *Acta psychiatrica Scandinavica*, 153(1), 54.

Weintraub D, et al. (2025) Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example. *Movement disorders : official journal of the Movement Disorder Society*, 40(3), 468.

Güller U, et al. (2025) Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3142.

Giurini L, et al. (2025) Lower Neighborhood-Level Socioeconomic Status Is Associated with Lower Colorectal Cancer Screening Uptake in the Southern Community Cohort Study. *Cancer prevention research (Philadelphia, Pa.)*, 18(6), 355.

Albayyaa M, et al. (2025) Hormonal Therapy Patterns in Older Men with Prostate Cancer in the United States, 2010-2019. *Cancers*, 17(19).

Min S, et al. (2025) Iron Consumption and Colorectal Cancer in Korean Adults: A Prospective Cohort Study. *Nutrients*, 17(8).

Parikh RR, et al. (2025) Associations Between Cancer and Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. *Mayo Clinic proceedings. Innovations, quality & outcomes*, 9(4), 100634.

Zhang N, et al. (2025) Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I

Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3194.

Koric A, et al. (2025) Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis. Cancer, 131(22), e70164.

Fan L, et al. (2025) Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial. Cancer cell.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer research communications, 5(3), 444.

Sutkus LT, et al. (2025) Experimentally induced colitis impacts myelin development and home-cage behavior in young pigs regardless of supplementation with oral gamma-cyclodextrin-encapsulated tributyrin. Frontiers in neuroscience, 19, 1484497.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 965.

Hu L, et al. (2025) HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. Med (New York, N.Y.), 6(6), 100575.

Li H, et al. (2025) IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial. Med (New York, N.Y.), 6(5), 100573.

Takemoto K, et al. (2025) DGK? Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. Cancer medicine, 14(5), e70710.

Lode HN, et al. (2025) Fc? Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3692.

Moseley GA, et al. (2025) Cumulative effects of training at different weekly energy expenditures on cardiorespiratory fitness and markers of metabolic syndrome in STRRIDE-Extension. Journal of applied physiology (Bethesda, Md. : 1985), 138(6), 1532.